Keywords: gsk, cervarix, effective, ph, iii, study, interim

GSK's Cervarix 100% effective in Ph III study

Article | 09 July 2007

Print This

An interim analysis of data from a Phase III trial of GlaxoSmithkline's cervical cancer vaccine candidate Cervarix indicates that it ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in